+
+
Stay Informed
TEER

TRICLIP™ TRANSCATHETER TRICUSPID VALVE REPAIR SYSTEM

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option to improve quality of life (QoL) and functional status in patients with symptomatic severe tricuspid regurgitation, despite optimal medical therapy, who are at intermediate or greater risk for surgery.1

THE STANDARD OF
CARING FOR TR

The TriClip Transcatheter Edge-to-Edge Repair (TEER) system is the only TEER device intentionally designed for the tricuspid valve. With stable navigation and precise delivery,2-5 TriClip TEER is the only tricuspid device proven to reduce risk of heart failure hospitalization and improve quality of life, relative to optimal medical therapy.6 In both randomized and real-world studies, TriClip TEER has proven:

  • Exceptional safety profile9,10
  • Maximized effectiveness in tricuspid regurgitation (TR) reduction6,7
  • Life Changing Improvements to heart failure hospitalization risk and quality of life6,7,9,10

A state-of-the-art treatment option for patients at intermediate
or greater risk for surgery

TriClip TEER is a low-risk,11 non-surgical treatment option for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation, despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.2

  • Transcatheter beating heart procedure
    - no cardiopulmonary bypass
  • Allows for real-time positioning and
    repositioning to optimize TR reduction
  • Femoral venous access
  • Can be used in a standard cath lab or hybrid room
  • No pre-procedural CT required
  • Fast recovery times; many patients go home
    the next day8
  • Patients with severe tricuspid regurgitation have significantly impaired quality of life12
    • Shortness of breath
    • Peripheral edema
    • Ascites
    • Fatigue
    • Declining exercise capacity
  • Current treatment options have limitations

    Medical therapy for TR has little impact on TR reduction – 2 year data6

     
    66%
    of patients with severe functional tricuspid regurgitation die within 5 years of medical management13
     



    Most patients receive medical management until right heart failure or end-organ dysfunction appears.14

  • Surgery is high risk and often not optimal15,16

    Surgery for TR is uncommon. Factors prohibiting surgery include:

    • Limited clinical evidence15
    • Multiple comorbidities15
    • Advanced age15
    • High rate of adverse events17,18


    Long-term survival estimates for patients undergoing
    surgical tricuspid valve replacement or repair11

EXCEPTIONAL SAFETY9,10

MAXIMIZED EFFECTIVENESS6,7

LIFE-CHANGING IMPACT6,7,9,10

The TriClip™ G5 Transcatheter Edge-to-Edge Repair System empowers you with stable navigation and precise delivery2,5
for complex conditions.

EPIC™ SUPRA AORTIC STENTED TISSUE VALVE FEATURES
1
2
3
4
5
6
7
8
    • Provides stability and precision during steering and positioning
    • Multiaxis steering to enable navigation across all lines of coaptation
  2. Flexes and extends delivery catheter to steer down to the valve plane
  3. Enables movement in septal or lateral direction
  4. Straightens and curves guide for height adjustment above the valve

  5. Designed for the tricuspid anatomy2,14,15

    • Provides adequate height over the valve
    • Maintains coaxial position during steering and positioning
    • Allows sweeping away from the septum to optimize delivery catheter position while maintaining perpendicularity to the valve plane
  6. Designed for direct access to the tricuspid valve2,14,15
  7. Confirm and optimize leaflet grasping
  8. Implant and gripper line detachment

Delivery Catheter (DC) Handle

  • Handle has integrated gripper levers and reduced flush volume.

    • Arm Positioner

  • Hard stop within arm positioner in open direction.

    • Release Pin

  • Finger hold to pull and initiate clip deployment.

    • Lock Line Release Latch

  • Releases one end of lock line at time of deployment.

    • Lock Knob

  • Discrete lock and unlock positions and no blue line.

    • Delivery System (DS) Attach

  • Spring-loaded attachment slides into stabilizer rail. Replaces black screw.

    • Stabilizer

  • Stabilizer rail and handles to support the movement of the delivery system.

    • Guide Attach

  • Spring-loaded attachment with pins for insertion into stabilizer dock. Replaces black screws and the need to tighten screw to secure position.

    • Guide Attachment Braking System

  • Allows for adjustable guide positioning and holds guide catheter position. Replaces black screw.

    • Built-in DC Fastener

  • Rotation of fastener counterclockwise secures delivery catheter. Replaces black screw.

    • EASY HANDLING 

    • Quick, secure docking with spring-loaded attachments for easy connection
    • Precise locking with binary lock knob to support consistent performance
    • Built-in fastener for easy securement of the DC

    PRECISE POSITIONING 

    • New guide attachment with braking system maintains desired positioning for enhanced control
    • Controlled movement with redesigned stabilizer rail and handles
    • Responsive new handle design capable of delivering 1:1 rotation

    INTUITIVE DEPLOYMENT 

    • New lock knob offers easy and straightforward lock line release and removal
    • Hard stop within arm positioner reduces dependence on visual indicators for more control
    • Disconnect with ease using new release pin with finger hold to initiate deployment

    Test(s) performed by and data on file at Abbott.

    • Building on a legacy of unmatched TEER expertise19

      TriClip™ implants use the same proven leaflet repair technology as our MitraClip™ Transcatheter Edge-to-Edge Repair (TEER) implants. TriClip TEER is the clip-based technology physicians know and trust, with a delivery system uniquely designed for the tricuspid valve.

      TriClip implant features:1

      • Elgiloy® implants with nitinol grippers
      • Polyester cover designed to promote tissue growth
      • Magnetic resonance conditional to 3 Tesla†

      †Static magnetic field of 1.5 T or 3 T; maximum spatial gradient in static field of 4000 gauss/cm; maximum whole-body averaged specific absorption rate (SAR) of 2 W/kg for 60 minutes of continuous radiofrequency.
       

    • Optimized leaflet capture

      Optimized leaflet capture for consistent TR reduction with the TriClip G5 TEER System

      • Wide grasp opening allows full leaflet insertion20
      • Designed to distribute retention forces along the entire inserted leaflet length21
      • Four or six rows of short frictional elements designed to provide atraumatic leaflet engagement21
    • Broad range of sizes for tailored treatment

      Four implant sizes are available for patient-specific therapy with the TriClip G5 TEER System.1

    CLINICAL DATA

    See the latest clinical data for the Triclip™ Transcatheter Tricuspid Valve Repair System.

    See Clinical Data

    Find a TriClip TEER certified
    physician near me

    Use this tool to refer a patient or consult with a certified implanting physician near you.

    Show nearest:
    Filter by:

    MAT-2401619 v8.0 | Item approved for U.S. use only.

    References
    1. TriClip G5 System IFU
    2. Abbott. Data on file. PS2203200
    3. Abbott. Data on file. PS2203401
    4. Abbott. Data on file. PS2203500
    5. Abbott. Data on file. PS2203501
    6. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal Randomized Trial. Circulation. March 30, 2025. doi:10.1161/CIRCULATIONAHA.125.074536
    7. Estevez-Loureiro R. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 2-year Outcomes from the bRIGHT Trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
    8. Adams D, Sorajja P, et al. TRILUMINATE Pivotal: Outcomes of All Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented at TCT on October 24, 2023; San Francisco, CA; USA.
    9. Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. Published online 2025;85(3):235-246. doi:10.1016/j.jacc.2024.10.08
    10. Lurz P, Rommel KP, Schmitz T, et al. Real-world 1-year results of tricuspid edge-to-edge repair from the bRIGHT study. J Am Coll Cardiol. 2024;84(7):607-616. doi:10.1016/j.jacc.2024.05.006
    11. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. NEJM. March 4, 2023. doi: 10.1056/NEJMoa2300525.
    12. www.mayoclinic.org. Accessed February 2024
    13. Benfari G, Antoine C, Mille WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140(3):196-206.
    14. Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71(25):2935-2956.
    15. Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, et al. Tricuspid regurgitation is a public health crisis [published online ahead of print November 9, 2019]. Prog Cardiovasc Dis. 2019;62(6):447-451. Doi:10.1016/j.pcad.2019.10.009.
    16. Wong WK, Chen SW, Chou AH, et al. Late outcomes of valve repair versus replacement in isolated and concomitant tricuspid valve surgery: a nationwide cohort study. J Am Heart Assoc. 2020;9(8):e015637. doi:10.1161/JAHA.119.015637.
    17. Zack CJ, Fender EA, Chandrashekar P, et al, National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. 2017;70(24):2953–2960. doi:10.1016/j.jacc.2017.10.039.
    18. Chen Q, Bowdish ME, Malas J, et al. Isolated tricuspid operations: The Society of Thoracic Surgeons Adult cardiac surgery database analysis. Ann Thorac Surg. 2023;115(5):1162–1170. doi:10.1016/j.athoracsur.2022.12.041.
    19. Data on File at Abbott.
    20. Abbott. Data on file. RPT2139672
    21. Test(s) performed by and data on file at Abbott. (RPT2133700, RPT2122822-R, RPT2124838-R)
    Important Safety Information

    Rx Only

    TRICLIP™ G5 SYSTEM

    INDICATION FOR USE

    The TriClip™ G5 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

    CONTRAINDICATIONS

    The TriClip™ G5 System is contraindicated for use in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

    POTENTIAL ADVERSE EVENTS

    The following events have been identified as possible complications of the TriClip™ G5 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment / surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and Heparin Induced Thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and Transesophageal echocardiogram (TEE) -related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension / hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement / rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

    YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

    U.S. VISITOR INTERNATIONAL VISITOR

    YOU ARE ABOUT TO LEAVE
    www.structural­heart.abbott

    You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

    OkCancel
    +